Browsing Tag
asthma biologics
2 posts
What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
New Dupilumab analyses highlight immune modulation claims. Read how Regeneron Pharmaceuticals is testing durability, reimbursement logic, and long-term strategy.
Can GSK’s Exdensur transform asthma biologics with just two doses per year?
GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy.